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Managing blood pressure in older adults
Age alone is no barrier to treatment
Stephen Makin clinical lecturer in geriatric medicine, David J Stott David Cargill professor of geriatric
medicine
Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
In a recent paper in The BMJ, Liv and colleagues reported the
results of a large cohort study investigating the link between
blood pressure and mortality in community dwelling Chinese
people with a mean age of 92 years.1 Studies of very elderly
people are challenging and rarely performed so these data are
of particular interest. Both high and low systolic blood pressure
were linked to an increase in mortality (a “U shaped curve”
relation). Systolic blood pressure >154 mm Hg was associated
with increased cardiovascular mortality, and <107 mm Hg with
non-cardiovascular death.
The finding that low systolic blood pressure predicts increased
risk of death is consistent with many other epidemiological
studies in older people. Although low blood pressure may in
itself cause harm, it is also likely to be a marker of ill health,
with systolic blood pressure falling for up to two years before
death.2 Any link between high systolic pressure and mortality
has been much less consistent in later life. In very elderly people
(≥85 years) an inverse linear relation has been reported, with
lowest mortality at the highest pressures,3 4 but health status may
play a major part in driving these associations.4 This is in
contrast to epidemiological data for younger or middle aged
people, in whom high pressure is clearly and consistently
associated with increased risk of fatal and non-fatal
cardiovascular events.5
How should these data influence decisions on use of
antihypertensive drugs in very elderly people? Here we must
be mindful of the fact that observational data have serious
limitations. Even the most rigorously adjusted analyses cannot
rule out residual confounding and reverse causality. Randomised
controlled trials remain the gold standard for informing treatment
decisions, and a substantial body of such evidence exists to
guide treatment of hypertension in older adults.
Evidence says aim low
In a Cochrane review and meta-analysis of randomised trials of
treatment of hypertension in people aged over 60,
antihypertensive drugs reduced cardiovascular morbidity and
both total and cardiovascular mortality.6 People aged over 80
have also been shown to benefit from drug treatment of high
blood pressure, although there are fewer data in this age group.
In the hypertension in the very elderly trial (HYVET), people
with sustained systolic blood pressure >160 mm Hg were
randomised to antihypertensive drugs or placebo. Treatment
reduced systolic blood pressure from a baseline 173 mm Hg to
143 mm Hg (compared with 158 mm Hg on placebo), leading
to a decrease in stroke, heart failure, and total mortality.7
However, for selected patients, we should probably be aiming
lower.
The Systolic Blood Pressure Intervention Trial (SPRINT) found
benefits from targeting a systolic blood pressure <120 mm Hg
in participants with mean age of 68 years and systolic >130 mm
Hg8; in a prespecified subgroup of people aged over 75 intensive
antihypertensive treatment achieved a mean systolic of 123 mm
Hg and led to a substantial reduction in cardiovascular events
and total mortality compared with standard care with mean
systolic pressure of 135 mm Hg.9 In common with most
randomised trials, SPRINT participants were generally fitter
with less multimorbidity and polypharmacy than patients in a
clinical setting. There was a penalty associated with intensive
treatment—an increase in adverse events including hypotension,
syncope, acute kidney injury, and electrolyte disturbance, seen
across all trial participants.8
Consider overall health
For selected older people, reduction of blood pressure aiming
to prevent cardiovascular disease and prolong life will be a high
priority—and there is potential for further gain from setting a
low treatment target. The most recent 2017 American College
of Cardiology/American Heart Association Task Force
guidelines (including the evidence from SPRINT)10 recommend
a target systolic blood pressure of <130 mm Hg for ambulatory
community dwelling people older than 65.
However for some, such as people who are very frail or have
complex comorbidity or limited life expectancy,
antihypertensive drugs are likely to be irrelevant or harmful.
The above guidelines recommend a more guarded approach for
people with a high burden of comorbidity and limited life
expectancy; clinical judgment, patient preference, and a team
based approach to assess risks and benefits should be used in
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decisions regarding intensity of treatment and choice of
antihypertensive drugs.
What should be done for older people with low systolic blood
pressure? Evidence is limited, but it seems reasonable to avoid
prescribing medicines likely to further reduce blood pressure.
For those taking antihypertensive drugs, the risks and benefits
associated with reducing or stopping treatment are also unclear.11
However, it is sensible to reduce or stop antihypertensives in
patients with adverse effects such as syncope or acute kidney
injury associated with low pressure.
Shared decision making is particularly important when
considering preventive treatments for very elderly people. The
priorities for older people with hypertension (and their carers)
can vary greatly. For some, the option of taking antihypertensive
drugs for longer term gain will be attractive. Others look for
faster and more noticeable benefit from any medicine taken,
with clear improvement of symptoms and enhanced quality of
life. The clinician’s role is to support patients navigating this
decision, in line with their individual preferences.
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